Title:
Clinical perspectives towards improving risk stratification strategy for renal transplantation outcomes in Indian patients

dc.contributor.authorVijay Kher
dc.contributor.authorVivek B. Kute
dc.contributor.authorSarbeswar Sahariah
dc.contributor.authorDeepak S. Ray
dc.contributor.authorDinesh Khullar
dc.contributor.authorSandeep Guleria
dc.contributor.authorShyam Bansal
dc.contributor.authorSishir Gang
dc.contributor.authorAnil Kumar Bhalla
dc.contributor.authorJai Prakash
dc.contributor.authorAbi Abraham
dc.contributor.authorSunil Shroff
dc.contributor.authorMadan M. Bahadur
dc.contributor.authorPratik Das
dc.contributor.authorUrmila Anandh
dc.contributor.authorArpita Ray Chaudhury
dc.contributor.authorManoj Singhal
dc.contributor.authorJatin Kothari
dc.contributor.authorSree Bhushan Raju
dc.contributor.authorDilip Kumar Pahari
dc.contributor.authorG. Vishwanath Siddini
dc.contributor.authorG. Sudhakar
dc.contributor.authorSantosh Varughese
dc.contributor.authorTarun K. Saha
dc.date.accessioned2026-02-07T11:02:34Z
dc.date.issued2022
dc.description.abstractGraft loss and rejections (acute/chronic) continue to remain important concerns in long-term outcomes in kidney transplant despite newer immunosuppressive regimens and increased use of induction agents. Global guidelines identify the risk factors and suggest a framework for management of patients at different risk levels for rejection; however, these are better applicable to deceased donor transplants. Their applicability in Indian scenario (predominantly live donor program) could be a matter of debate. Therefore, a panel of experts discussed the current clinical practice and adaptability of global recommendations to Indian settings. They also took a survey to define risk factors in kidney transplants and provide direction toward evidence- and clinical experience-based risk stratification for donor/recipient and transplant-related characteristics, with a focus on living donor transplantations. Several recipient related factors (dialysis, comorbidities, and age, donor-specific antibodies [DSAs]), donor-related factors (age, body mass index, type - living or deceased) and transplantation related factors (cold ischemia time [CIT], number of transplantations) were assessed. The experts suggested that immunological conflict should be avoided by performing cytotoxic cross match, flow cross match in all patients and DSA-(single antigen bead) whenever considered clinically relevant. HLA mismatches, presence of DSA, along with donor/recipient age, CIT, etc., were associated with increased risk of rejection. Furthermore, the panel agreed that the risk of rejection in living donor transplant is not dissimilar to deceased donor recipients. The experts also suggested that induction immunosuppression could be individualized based on the risk stratification. © 2022 Wolters Kluwer Medknow Publications. All rights reserved.
dc.identifier.doi10.4103/ijot.ijot_28_21
dc.identifier.issn22120017
dc.identifier.urihttps://doi.org/10.4103/ijot.ijot_28_21
dc.identifier.urihttps://dl.bhu.ac.in/bhuir/handle/123456789/41479
dc.publisherWolters Kluwer Medknow Publications
dc.subjectAcute rejection
dc.subjectdonor-specific antibody
dc.subjecthuman leukocyte antigens
dc.subjectimmunosuppression
dc.subjectIndian patients
dc.subjectliving donors
dc.subjectrenal transplantation
dc.titleClinical perspectives towards improving risk stratification strategy for renal transplantation outcomes in Indian patients
dc.typePublication
dspace.entity.typeArticle

Files

Collections